-$0.39 Earnings Per Share Expected for REDHILL BIOPHAR/S (RDHL) This Quarter

Analysts forecast that REDHILL BIOPHAR/S (NASDAQ:RDHL) will post earnings per share of ($0.39) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for REDHILL BIOPHAR/S’s earnings, with estimates ranging from ($0.40) to ($0.38). REDHILL BIOPHAR/S reported earnings of ($0.50) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 22%. The firm is expected to report its next earnings report on Thursday, February 28th.

According to Zacks, analysts expect that REDHILL BIOPHAR/S will report full year earnings of ($1.76) per share for the current financial year, with EPS estimates ranging from ($1.80) to ($1.67). For the next financial year, analysts forecast that the business will post earnings of ($1.41) per share, with EPS estimates ranging from ($1.80) to ($1.10). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for REDHILL BIOPHAR/S.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last released its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.40) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.40). The firm had revenue of $2.21 million for the quarter, compared to the consensus estimate of $2.54 million. REDHILL BIOPHAR/S had a negative return on equity of 112.99% and a negative net margin of 461.55%.

Several equities analysts have recently weighed in on RDHL shares. HC Wainwright set a $36.00 target price on REDHILL BIOPHAR/S and gave the company a “buy” rating in a research report on Wednesday, November 14th. Zacks Investment Research raised REDHILL BIOPHAR/S from a “hold” rating to a “buy” rating and set a $8.50 target price on the stock in a research report on Thursday, September 6th. Finally, ValuEngine raised REDHILL BIOPHAR/S from a “sell” rating to a “hold” rating in a research report on Wednesday, October 3rd. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $20.81.

Shares of NASDAQ RDHL traded up $0.02 during trading hours on Monday, hitting $7.05. 491,989 shares of the company traded hands, compared to its average volume of 138,266. The company has a market cap of $149.55 million, a P/E ratio of -2.71 and a beta of 0.88. REDHILL BIOPHAR/S has a 12 month low of $4.40 and a 12 month high of $11.49.

A number of institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC grew its position in REDHILL BIOPHAR/S by 8.6% in the 2nd quarter. ARK Investment Management LLC now owns 112,648 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 8,894 shares during the last quarter. Creative Planning grew its position in REDHILL BIOPHAR/S by 16.1% in the 3rd quarter. Creative Planning now owns 162,950 shares of the biotechnology company’s stock valued at $1,439,000 after acquiring an additional 22,561 shares during the last quarter. Ibex Investors LLC grew its position in REDHILL BIOPHAR/S by 5.4% in the 3rd quarter. Ibex Investors LLC now owns 527,000 shares of the biotechnology company’s stock valued at $4,653,000 after acquiring an additional 27,000 shares during the last quarter. JPMorgan Chase & Co. grew its position in REDHILL BIOPHAR/S by 61.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 73,878 shares of the biotechnology company’s stock valued at $652,000 after acquiring an additional 28,102 shares during the last quarter. Finally, Disciplined Growth Investors Inc. MN bought a new position in REDHILL BIOPHAR/S in the 3rd quarter valued at $295,000. 32.27% of the stock is currently owned by institutional investors.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.

See Also: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply